Brecanavir (INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV.[1]

Quick facts Clinical data, ATC code ...
Brecanavir |
|
| ATC code | |
|---|
|
[(3R,3aS,6aR)-2,3,3a,4,5,6a-Hexahydrofuro[5,4-b]furan-3-yl] N-[(2S,3R)-4-(1,3-benzodioxol-5-ylsulfonyl-(2-methylpropyl)amino)-3-hydroxy-1-[4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl]butan-2-yl]carbamate
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
|
| Formula | C33H41N3O10S2 |
|---|
| Molar mass | 703.82 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
O=S(=O)(c2ccc1OCOc1c2)N(CC(C)C)C[C@@H](O)[C@@H](NC(=O)O[C@@H]3[C@@H]4CCO[C@@H]4OC3)Cc6ccc(OCc5nc(sc5)C)cc6
|
InChI=1S/C33H41N3O10S2/c1-20(2)14-36(48(39,40)25-8-9-29-30(13-25)45-19-44-29)15-28(37)27(35-33(38)46-31-17-43-32-26(31)10-11-41-32)12-22-4-6-24(7-5-22)42-16-23-18-47-21(3)34-23/h4-9,13,18,20,26-28,31-32,37H,10-12,14-17,19H2,1-3H3,(H,35,38)/t26-,27-,28+,31-,32+/m0/s1 YKey:JORVRJNILJXMMG-OLNQLETPSA-N Y
|
N Y (what is this?) (verify) |
Close
In December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation.[2]